NXTS vs REGN vs VRTX Stock Comparison

Nexentis Technologies, Regeneron Pharmaceuticals and Vertex Pharmaceuticals Prices as of Nov 13, 2026 Peers: Industry group

Head to Head

10 decided of 12

Regeneron Pharmaceuticals leads on 6 of the 12 questions below (Regeneron Pharmaceuticals 6, Vertex Pharmaceuticals 4). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionNXTSREGNVRTXLeader
Larger companyMarket capitalisation $344.41K $97.85B $138.29B VRTX
Cheaper on earningsLower P/E, profitable companies only 0.0x 20.3x 34.8x REGN
Cheaper on forward earningsLower price / next fiscal year consensus EPS — 14.8x 30.4x REGN
Faster revenue growthRevenue growth, trailing twelve months -4,237.5% +18.6% +10.5% REGN
More profitableNet margin, trailing twelve months — 28.5% 30.7% VRTX
Better return on capitalReturn on invested capital — 11.9% — –
Less leveragedLower net debt / EBITDA 0.8x -1.4x -0.4x REGN
Higher dividend yieldTrailing dividend yield 0.00% 0.00% 0.00% –
Better 1-year returnPrice return, last 12 months -90.3% +37.5% +24.0% REGN
Better 5-year returnAnnualised price return, 5 years -82.4%/yr +8.7%/yr +23.5%/yr VRTX
Less volatileAnnualised volatility, 1 year 235.4% 33.9% 29.5% VRTX
Higher overall scoreMean of the five percentile scores vs peers 18/100 73/100 73/100 REGN

Percentile Scorecard

NXTSREGNVRTX

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisNXTSREGNVRTX
Valuation 7 #612 of 660 89 #75 of 660 77 #152 of 660
Growth 6 #585 of 619 50 #308 of 619 46 #333 of 619
Profitability 22 #462 of 595 92 #48 of 595 93 #40 of 595
Financial Health 38 #423 of 683 71 #199 of 683 55 #311 of 683
Shareholder Returns – 63 #170 of 459 92 #37 of 459
Overall 18 73 73
  • NXTS ranked among 695 companies in Pharmaceuticals and Biotechnology
  • REGN ranked among 695 companies in Pharmaceuticals and Biotechnology
  • VRTX ranked among 695 companies in Pharmaceuticals and Biotechnology

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodNXTSREGNVRTXSPY
1 month +229.2%+22.8%+8.0% -2.0%
3 months +12.0%+18.9%+6.5% -2.8%
6 months -52.0%+36.8%+23.3% +2.0%
Year to date -81.8%+23.8%+18.8% +10.6%
1 year -90.3%+37.5%+24.0% +12.2%
3 years -99.6%+20.4%+45.6% +68.1%
3 years, per year -84.2%+6.4%+13.3% +18.9%
5 years -100.0%+51.4%+187.6% +61.4%
5 years, per year -82.4%+8.7%+23.5% +10.1%
10 years -100.0%+127.6%+485.4% +248.5%
10 years, per year -61.8%+8.6%+19.3% +13.3%

Risk

MeasureNXTSREGNVRTXSPY
Volatility, 1Y 235.4%33.9%29.5% 13.6%
Downside volatility, 1Y 158.4%30.8%26.1% 13.9%
Beta vs S&P 500, 1Y 4.330.350.43 1.00
Return / volatility, 1Y -0.381.110.81 0.90
Max drawdown, 5Y -100.0%-59.8%-29.1% -25.4%
From 52-week high -90.5%-1.8%-3.6% -3.2%
52-week high $22.54$973.36$558.71 $779.14
52-week low $0.48$600.66$421.03 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleNXTSREGNVRTX
P/E now vs peer median 0.0xmedian 17.0x 20.2xmedian 17.0x 34.3xmedian 17.0x
P/S now vs peer median 0.0xmedian 8.4x 5.8xmedian 8.4x 10.5xmedian 8.4x
EV/EBITDA now vs peer median 0.8xmedian 14.6x 16.7xmedian 14.6x 29.7xmedian 14.6x
P/FCF now vs peer median -0.1xmedian 19.0x 25.4xmedian 19.0x 42.6xmedian 19.0x
P/B now vs peer median 0.2xmedian 2.0x 2.9xmedian 2.0x 6.5xmedian 2.0x
PEG now vs peer median 0.00median 0.43 2.23median 0.43 6.39median 0.43

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsNXTSREGNVRTX
Revenue -$8.94M $16.90B $12.95B
Gross profit – $14.49B $11.08B
Operating income -$10.88M $4.86B $4.30B
Net income -$16.14M $4.82B $3.98B
Free cash flow -$4.50M $3.83B $3.20B
R&D $798.00K $6.60B $4.25B
EPS (diluted) $-98.21 $45.62 $15.58
Cash & equivalents $7.62M $3.66B $4.98B
Total debt $422.00K $1.99B $4.50B
Shares (diluted) 163.23K 105.60M 255.20M
Enterprise value -$25.09M $63.20B $106.02B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricNXTSREGNVRTX
P/E 0.0x 20.2x 34.3x
P/FCF -0.1x 25.4x 42.6x
P/Operating cash flow -0.1x 20.1x 37.0x
P/S 0.0x 5.8x 10.5x
P/B 0.2x 2.9x 6.5x
P/Tangible book -0.2x 3.0x 11.0x
EV/EBITDA 0.8x 16.7x 29.7x
EV/EBIT 0.7x 18.5x 31.3x
EV/Revenue 0.9x 5.3x 10.4x
EV/FCF 1.8x 23.5x 42.1x
EV/Operating cash flow 1.8x 18.5x 36.5x
PEG (3Y EPS CAGR) 0.00 2.23 6.39

Growth

14 metrics
MetricNXTSREGNVRTX
Revenue growth (1Y) -4,238% 18.6% 10.5%
Revenue CAGR (3Y) -182.9% 8.9% 10.3%
Gross profit growth (1Y) – 19.1% 9.5%
Gross profit CAGR (3Y) – 8.8% 9.3%
Operating income growth (1Y) -127.3% 31.9% 7.8%
Operating income CAGR (3Y) -23.5% 4.8% 3.5%
Net income growth (1Y) -70.1% 5.2% 8.2%
Net income CAGR (3Y) -42.2% 6.5% 4.6%
EPS growth (1Y) -666.2% 6.8% 9.2%
EPS CAGR (3Y) -52.0% 9.0% 5.4%
Operating cash flow growth (1Y) -62.8% -4.4% -0.6%
Operating cash flow CAGR (3Y) -0.4% -2.5% -5.5%
Free cash flow growth (1Y) -65.5% -9.4% -4.0%
Free cash flow CAGR (3Y) -0.7% -6.0% -8.7%

Profitability

14 metrics
MetricNXTSREGNVRTX
Gross margin – 85.8% 85.5%
EBITDA margin – 31.8% 35.1%
Operating margin – 28.8% 33.2%
Pretax margin – 33.7% 36.7%
Net margin – 28.5% 30.7%
FCF margin – 22.6% 24.7%
Operating cash flow margin 49.6% 28.7% 28.5%
Return on equity -218.6% 14.0% 19.3%
Return on assets -92.0% 10.6% 13.2%
Return on invested capital – 11.9% –
Return on capital employed -73.7% 13.2% 17.2%
Asset turnover -0.5x 0.4x 0.4x
Cash conversion (OCF / net income) 0.3x 1.0x 0.9x
Stock comp / revenue -11.0% 6.0% 5.2%

Financial Health

11 metrics
MetricNXTSREGNVRTX
Debt / assets 2.3% 4.5% 13.7%
Debt / equity 0.2x 0.1x 0.2x
Net debt / EBITDA 0.8x -1.4x -0.4x
Debt / FCF -0.1x 0.5x 1.4x
Liabilities / assets 89.8% 24.6% 36.1%
Equity / assets 10.2% 75.4% 63.9%
Interest coverage – 104.2x 93.0x
Current ratio 3.7x 3.4x 2.3x
Quick ratio 3.2x 2.7x 1.7x
Cash ratio 3.2x 1.5x 1.3x
Altman Z-score -6.11 7.73 8.70

Shareholder Returns

7 metrics
MetricNXTSREGNVRTX
Dividend yield – 0.4% –
Net buyback yield -2,794% 2.1% 0.7%
Shareholder yield -2,794% 2.5% 0.7%
Payout ratio (earnings) – – –
Payout ratio (FCF) – – –
Dividend growth (1Y) – – –
Dividend CAGR (3Y) – – –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusNXTSREGNVRTX
Forward P/E – 14.8xFY2026 30.4xFY2026
EPS, next fiscal year – $64.62FY2026 $17.71FY2026
EPS growth, next FY – +45.8%FY2026 -3.7%FY2026
EPS growth, the year after – +13.6% +20.2%
Revenue, next fiscal year – $18.08BFY2026 $12.68BFY2026
Revenue growth, next FY – +26.1%FY2026 +5.9%FY2026
Revenue growth, the year after – +14.6% +19.2%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersNXTSREGNVRTX
Held by institutions – 66.2% 95.1%
Institutions holding – 1,329 1,747
Change in shares held, QoQ – +3.8% +3.9%
Institutions buying – 607 904
Institutions selling – 534 605
Buyers to sellers – 1.14 1.49

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

NXTSREGNVRTX
NXTS 1.00 0.03 0.05
REGN 0.03 1.00 0.43
VRTX 0.05 0.43 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, NXTS, REGN and VRTX?

Vertex Pharmaceuticals (VRTX) is the largest by market capitalisation: Nexentis Technologies (NXTS) $344.41K, Regeneron Pharmaceuticals (REGN) $97.85B, Vertex Pharmaceuticals (VRTX) $138.29B.

Which stock is cheaper, NXTS, REGN and VRTX?

Regeneron Pharmaceuticals (REGN) trades on the lowest price-to-earnings ratio (Nexentis Technologies (NXTS) 0.0x, Regeneron Pharmaceuticals (REGN) 20.3x, Vertex Pharmaceuticals (VRTX) 34.8x). On next year's consensus earnings, Regeneron Pharmaceuticals (REGN) is cheapest (Regeneron Pharmaceuticals (REGN) 14.8x, Vertex Pharmaceuticals (VRTX) 30.4x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which company is growing faster?

Regeneron Pharmaceuticals (REGN) grew revenue fastest over the trailing twelve months: Nexentis Technologies (NXTS) -4,237.5%, Regeneron Pharmaceuticals (REGN) +18.6%, Vertex Pharmaceuticals (VRTX) +10.5%.

Which company is more profitable?

Vertex Pharmaceuticals (VRTX) has the highest net margin (Regeneron Pharmaceuticals (REGN) 28.5%, Vertex Pharmaceuticals (VRTX) 30.7%).

Which stock has performed better?

Over the past year Regeneron Pharmaceuticals (REGN) returned the most: Nexentis Technologies (NXTS) -90.3%, Regeneron Pharmaceuticals (REGN) +37.5%, Vertex Pharmaceuticals (VRTX) +24.0%. Over five years, Vertex Pharmaceuticals (VRTX) compounded fastest (Nexentis Technologies (NXTS) -82.4%/yr, Regeneron Pharmaceuticals (REGN) +8.7%/yr, Vertex Pharmaceuticals (VRTX) +23.5%/yr). Returns are price only, before dividends.

Which stock is riskier?

By one-year price volatility, Vertex Pharmaceuticals (VRTX) has been the steadiest (Nexentis Technologies (NXTS) 235.4%, Regeneron Pharmaceuticals (REGN) 33.9%, Vertex Pharmaceuticals (VRTX) 29.5%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, NXTS, REGN and VRTX?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Regeneron Pharmaceuticals (REGN) leads on 6. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.